A61K 38/1725
Complement proteins
Official title: {Complement proteins, e.g. anaphylatoxin, C3a or C5a}
A61K38/1725 (Complement proteins) appears on 68 US grants and 148 published applications in this corpus.
Search patents in A61K- Granted patents
- 68
- Published applications
- 148
- Assignees
- 98
- Inventors
- 270
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 4 |
| 2009 | 1 | 1 |
| 2010 | 0 | 2 |
| 2011 | 0 | 5 |
| 2012 | 3 | 3 |
| 2013 | 1 | 10 |
| 2014 | 2 | 9 |
| 2015 | 4 | 5 |
| 2016 | 6 | 9 |
| 2017 | 4 | 6 |
| 2018 | 8 | 9 |
| 2019 | 8 | 12 |
| 2020 | 2 | 7 |
| 2021 | 6 | 16 |
| 2022 | 7 | 13 |
| 2023 | 4 | 7 |
| 2024 | 5 | 10 |
| 2025 | 3 | 5 |
| 2026 | 3 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Isolated antigen binding protein binding to a complement protein C5 and a method of detecting thereof16 Jun 2026US 12,655,201 B2Longbio Pharma (Suzhou) Co., Ltd.
- Hydrochloride salts of C5a receptor agonist peptides17 Feb 2026US 12,552,848 B2Board of Regents of the University of Nebraska
- C3d cellular and acellular vaccines for the prevention and treatment of cancer10 Feb 2026US 12,545,712 B2The Regents of the University of Michigan
- Synthesis and structure of high potency RNA therapeutics30 Dec 2025US 12,509,698 B2Arcturus Therapeutics, Inc.
- Compounds and compositions for intracellular delivery of therapeutic agents2 Sep 2025US 12,404,232 B2ModernaTX, Inc.
- Adeno-associated Virus Formulations1 Oct 2026US 2026/0295077 A14D Molecular Therapeutics Inc.
- Peptide compounds to regulate the complement system24 Sep 2026US 2026/0285907 A1Realta Holdings, LLC
- Synthesis and structure of high potency rna therapeutics10 Sep 2026US 2026/0265769 A1Arcturus Therapeutics, Inc.
- Factor b inhibitors and uses thereof13 Aug 2026US 2026/0232760 A1The Trustees of the University of Pennsylvania
- Aav variants for the treatment of dry amd16 Jul 2026US 2026/0199522 A1Adverum Biotechinologies, Inc.
Most cited
By later US patents
- Compounds and compositions for intracellular delivery of therapeutic agents143US 9,868,691 B2ModernaTX, Inc. · 2018
- Compounds and compositions for intracellular delivery of therapeutic agents62US 9,868,692 B2ModernaTX, Inc. · 2018
- Compounds and compositions for intracellular delivery of therapeutic agents50US 10,442,756 B2ModernaTX, Inc. · 2019
- Compounds and compositions for intracellular delivery of therapeutic agents42US 10,266,485 B2ModernaTX, Inc. · 2019
- Methods and compositions for the inhibition of interleukin-12 production34US 6,086,876 AThe Johns Hopkins University · 2000